Boehringer Ingelheim/Pfizer's Spiriva adds COPD exacerbations claim
This article was originally published in Scrip
Executive Summary
The US FDA has extended use of Boehringer Ingelheim's long-acting anticholinergic Spiriva HandiHaler (tiotropium bromide; licensed to Pfizer) to include reduction of exacerbations in patients with chronic obstructive pulmonary disease (COPD).